相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia
Llucia Alberti-Servera et al.
BLOOD (2021)
Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Alexandra Semchenkova et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Manon Queudeville et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
Christina Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
S. Modvig et al.
LEUKEMIA (2021)
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Patrick A. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Franco Locatelli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab
Rosemary Sutton et al.
PEDIATRIC BLOOD & CANCER (2021)
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
Marie-Emilie Dourthe et al.
LEUKEMIA (2021)
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
Irene Della Starza et al.
HEMASPHERE (2021)
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia
Amir Enshaei et al.
BLOOD (2020)
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement
Jack Bartram et al.
SEMINARS IN HEMATOLOGY (2020)
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
Franco Locatelli et al.
BLOOD CANCER JOURNAL (2020)
The value of 18F-FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation
Zixuan Zhao et al.
ONCOLOGY LETTERS (2020)
Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience
Marianne Ifversen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
Pietro Merli et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Isolated Extramedullary Relapse as a Poor Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
Ioanna Sakellari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma
Joseph A. DiGiuseppe et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
Henrik Knecht et al.
LEUKEMIA (2019)
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
Monika Brueggemann et al.
LEUKEMIA (2019)
Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia
Anna Karen Haugaard et al.
PEDIATRIC TRANSPLANTATION (2019)
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia
S. Modvig et al.
LEUKEMIA (2019)
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Peter Bader et al.
BLOOD ADVANCES (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga et al.
HAEMATOLOGICA (2018)
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia
N. Toft et al.
LEUKEMIA (2018)
Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia
Trausti Oskarsson et al.
PEDIATRIC BLOOD & CANCER (2018)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga et al.
HAEMATOLOGICA (2018)
Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation
Lea Sellmann et al.
BONE MARROW TRANSPLANTATION (2018)
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia
Federica Lovisa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Extramedullary Infiltration of Acute Lymphoblastic Leukemia in Multiple Organs on FDG PET/CT
Shuxin Zhang et al.
CLINICAL NUCLEAR MEDICINE (2018)
Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
David O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL
Matthias Woelfl et al.
BLOOD ADVANCES (2018)
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Prisca Theunissen et al.
BLOOD (2017)
Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG)
S Gupta et al.
LEUKEMIA (2017)
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Michaela Kotrova et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Extramedullary leukemia in children with acute myeloid leukemia: A population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO)
Heidi Kristine Stove et al.
PEDIATRIC BLOOD & CANCER (2017)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstrikova et al.
BLOOD CANCER JOURNAL (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation
Eva Rettinger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse
R. J. M. Bashford-Rogers et al.
LEUKEMIA (2016)
Coming of age: ten years of next-generation sequencing technologies
Sara Goodwin et al.
NATURE REVIEWS GENETICS (2016)
Treatment-related adverse events associated with amodified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia
Weili Sun et al.
PEDIATRIC BLOOD & CANCER (2016)
Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia
Katsutsugu Umeda et al.
PEDIATRIC TRANSPLANTATION (2016)
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
Michael A. Pulsipher et al.
BLOOD (2015)
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
Michael J. Borowitz et al.
BLOOD (2015)
Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?
M. A. Pulsipher et al.
BONE MARROW TRANSPLANTATION (2015)
Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Peter Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react
Cecile Pochon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia
Rosemary Sutton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Methodological Aspects of Minimal Residual Disease Assessment by Flow Cytometry in Acute Lymphoblastic Leukemia: A French Multicenter Study
Chantal Fossat et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2015)
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial
Michael A. Pulsipher et al.
BLOOD (2014)
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Adriana Balduzzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Patrick Schlegel et al.
HAEMATOLOGICA (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
Ajay Vora et al.
LANCET ONCOLOGY (2014)
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
Gannie Tzoneva et al.
NATURE MEDICINE (2013)
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
Wing Leung et al.
BLOOD (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe et al.
BLOOD (2011)
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
R. Handgretinger et al.
LEUKEMIA (2011)
Immunophenotype-defined sub-populations are common at diagnosis in childhood B-cell precursor acute lymphoblastic leukemia
N. F. Obro et al.
LEUKEMIA (2011)
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter et al.
BLOOD (2010)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
Peter Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL
E. Fronkova et al.
BONE MARROW TRANSPLANTATION (2008)
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone
Seoyeon Choi et al.
BLOOD (2007)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia
Lucie Sramkova et al.
PEDIATRIC BLOOD & CANCER (2007)
Localized relapse in bone marrow of extremities after allogeneic stem cell transplantation for acute lymphoblastic leukemia
T Endo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy?
P Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring
G Germano et al.
LEUKEMIA (2003)
Clonality analysis for antigen receptor genes: Preliminary results from the BIOMED-2 concerted action PL 96-3936
JHJM van Krieken et al.
HUMAN PATHOLOGY (2003)
Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL
P Bader et al.
LEUKEMIA (2002)
Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia
VHJ van der Velden et al.
LEUKEMIA (2001)
Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy
V de Haas et al.
LEUKEMIA (2001)
Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia
MM Bisschop et al.
LEUKEMIA (2001)
分享论文
